Date
- 2026 (46)
- 2025 (28)
- 2024 (17)
- 2023 (44)
- 2022 (38)
- 2021 (36)
- 2020 (58)
- 2019 (31)
- 2018 (46)
- 2017 (11)
- 2016 (44)
- 2015 (36)
- 2014 (10)
- 2013 (12)
- 2012 (3)
- 2011 (6)
- 2010 (27)
- 2009 (4)
- 2008 (15)
- 2007 (1)
- 2006 (4)
- 2005 (10)
- 2004 (4)
- 2003 (5)
- 2002 (7)
- 2001 (3)
- 2000 (8)
- 1999 (2)
- 1998 (2)
- 1997 (4)
- 1996 (3)
- 1995 (4)
- 1993 (10)
- 1992 (3)
- 1991 (12)
Sponsor content
594 result(s) found, displaying 21 to 30
-
Australian Public Assessment Report (AusPAR)Rhapsido (remibrutinib) has been approved for the treatment of chronic spontaneous urticaria (CSU) in adult patients who remain symptomatic despite H1 antihistamine treatment.
-
Prescription medicine registrationActive ingredients: lutetium (177Lu) vipivotide tetraxetan.
-
Prescription medicine registrationActive ingredients: capmatinib hydrochloride.
-
Jun-2026Prescription medicine evaluationActive ingredient: Secukinumab.
-
Prescription medicine decision summaryRhapsido has been approved for the treatment of chronic spontaneous urticaria (CSU) in adult patients who remain symptomatic despite H1 antihistamine treatment. Rhapsido contains the active ingredient remibrutinib.
-
May-2026Prescription medicine evaluationActive ingredient: ianalumab.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for AVLOIRE CR 400 carbamazepine 400 mg tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for AVLOIRE CR 200 carbamazepine 200 mg tablet blister pack.
-
Prescription medicine registrationActive ingredients: remibrutinib.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for MOVABEY omalizumab (rch) 75 mg solution for injection pre-filled pen.